CDA | Evidence Driven
CDA | Evidence Driven

Zytiga for metastatic Castration Resistant Prostate Cancer - Details

Détails

Fichiers
Generic Name:
Abiraterone acetate
État du projet:
Terminé
Domaine thérapeutique:
Metastatic Castration Resistant Prostate Cancer
Fabricant:
Janssen Inc.
Brand Name:
Zytiga
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0028-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
250 mg tablet
Tumour Type:
Genitourinary
Indications:
Metastatic Castration Resistant Prostate Cancer
Funding Request:
For asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients after failure of ADT (have not received prior chemotherapy)
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Janssen Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:

Fichiers

Provincial Funding Summary Résumé, financement provincial Afficher le PDF
Abiraterone Acetate (Zytiga) for mCRPC - pERC Final Recommendation Recommandation finale 22 octobre 2013 Afficher le PDF
Abiraterone Acetate (Zytiga) for mCRPC - Final Clinical Guidance Report Rapports d'orientation 22 octobre 2013 Afficher le PDF
Abiraterone Acetate (Zytiga) for mCRPC - Final Economic Guidance Report Rapports d'orientation 22 octobre 2013 Afficher le PDF
Abiraterone Acetate (Zytiga) for mCRPC - pERC Initial Recommendation Recommandation initiale 03 octobre 2013 Afficher le PDF
Abiraterone Acetate (Zytiga) - PAG Feedback on Initial Recommmendation Rétroaction 22 octobre 2013 Afficher le PDF
Abiraterone Acetate (Zytiga) - Manufacturer (Janssen) Feedback on Initial Recommendation Rétroaction 22 octobre 2013 Afficher le PDF
Abiraterone Acetate (Zytiga) - Patient Advocacy Group (CCSN) Feedback on Initial Recommendation Rétroaction 22 octobre 2013 Afficher le PDF
Abiraterone Acetate (Zytiga) - Patient Advocacy Group (CCSN) COI Declarations Rétroaction 22 octobre 2013 Afficher le PDF
Abiraterone Acetate (Zytiga) - Patient Advocacy Group (PCC) Feedback on Initial Recommendation Rétroaction 22 octobre 2013 Afficher le PDF
Abiraterone Acetate (Zytiga) - Patient Advocacy Group (PCC) COI Declarations Rétroaction 22 octobre 2013 Afficher le PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Dernière mise à jour : 06 novembre 2013